Status: Recruiting
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Participants needed: 78
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Ascentage Pharma Group Inc.Updated: Nov 4, 2025Locations: 1
Eligibility criteria
Age ≥ 18 years old [+6]
Patient previously treated with a murine double minute 2 (MDM2) inhibitor. [+4]